Halozyme Therapeutics Inc (HALO)

[biotechinvestor1]

Looking more and more like approaching a buy out by Roche/Genetech.

1) Projeta
2) Expansion of Mabthera SC to US
3) immunotherapy and Pegph20 collaboration with Genentech across multiple cancer targets starting in 17
4) SF office with former Genetech officer
5) Recent bylaws amendment
6) hiring freeze since the beginning of the year
7) Herceptin patent expiration in US. Enhanze to the rescue
8) Ventana diagnostic assay made by Roche

Why would Roche want to continue to pay royalties and milestones when they can buy Halozyme so cheap now?

It's a possibility also that other potential partners are viewing Halozyme as an eventual Roche acquisition and are therefore shying away from deal making.

We have seen this movie before. Phase 2 results are good. A rally ensues. Price is artificially depressed. And the company is bought out.